I-Mab (IMAB NASDAQ) stock market data APIs
$2.1454
0.15(7%)
as of July 3, 2025
Try our APIs with
free plan!
I-Mab Financial Data Overview
Price chart is built with
Anychart
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
Prev. Close
2.1454
Open
2.2943
High
2.3533
Low
2.1108
52 wk Range
0.595-3.075
Market Cap
176 M
Shares Outstanding
81 660 K
Revenue
3 492 K
EPS
-0.055
Beta
1.166
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get I-Mab data using free add-ons & libraries
Get I-Mab Fundamental Data
I-Mab Fundamental data includes:
- Net Revenue: 3 492 K
- EBITDA: -47 981 500
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-03
- EPS/Forecast: -0.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
I-Mab News
New
I-Mab reports 83% response rate for givastomig in gastric cancer study
ROCKVILLE - I-Mab (NASDAQ:IMAB), a clinical-stage biotech company currently valued at $188 million, announced positive Phase 1b data for its bispecific antibody givastomig in combination with nivoluma...
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or...
I-Mab's givastomig shows promising results in gastric cancer study
ROCKVILLE, MD - I-Mab (NASDAQ:IMAB), a clinical-stage biotech company whose stock has surged over 200% in the past six months, announced Monday that data from its first-in-human study of givastomig, a...
I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research
Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy ROCKVILLE, MD, June 30, 2025 (GLOBE NEWSWIRE) -- I-Mab...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
